Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1967 1
1968 4
1969 5
1970 2
1971 2
1972 1
1974 1
1975 5
1976 1
1977 2
1978 3
1979 3
1982 1
1983 5
1984 4
1985 2
1986 3
1987 6
1988 1
1989 8
1990 7
1991 16
1992 9
1993 8
1994 14
1995 15
1996 20
1997 21
1998 37
1999 40
2000 33
2001 42
2002 58
2003 83
2004 109
2005 121
2006 130
2007 178
2008 158
2009 200
2010 196
2011 195
2012 208
2013 253
2014 261
2015 266
2016 256
2017 235
2018 240
2019 247
2020 221
2021 173
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

3,576 results
Results by year
Filters applied: . Clear all
Page 1
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Knowler WC, et al. N Engl J Med. 2002 Feb 7;346(6):393-403. doi: 10.1056/NEJMoa012512. N Engl J Med. 2002. PMID: 11832527 Free PMC article. Clinical Trial.
The incidence of diabetes was 11.0, 7.8, and 4.8 cases per 100 person-years in the placebo, metformin, and lifestyle groups, respectively. The lifestyle intervention reduced the incidence by 58 percent (95 percent confidence interval, 48 to 66 percent) and metformin
The incidence of diabetes was 11.0, 7.8, and 4.8 cases per 100 person-years in the placebo, metformin, and lifestyle groups, respecti …
Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study.
Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, Bray GA, Schade DS, Temprosa MG, White NH, Crandall JP; Diabetes Prevention Program Research Group. Aroda VR, et al. J Clin Endocrinol Metab. 2016 Apr;101(4):1754-61. doi: 10.1210/jc.2015-3754. Epub 2016 Feb 22. J Clin Endocrinol Metab. 2016. PMID: 26900641 Free PMC article. Clinical Trial.
Participants were assigned to the placebo group (PLA) (n = 1082) or the metformin group (MET) (n = 1073) for 3.2 years; subjects in the metformin group received open-label metformin for an additional 9 years. ...B12 levels were assessed at 5 years (n = 857, n …
Participants were assigned to the placebo group (PLA) (n = 1082) or the metformin group (MET) (n = 1073) for 3.2 years; subjects in t …
Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.
Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S; VERIFY study group. Matthews DR, et al. Lancet. 2019 Oct 26;394(10208):1519-1529. doi: 10.1016/S0140-6736(19)32131-2. Epub 2019 Sep 18. Lancet. 2019. PMID: 31542292 Clinical Trial.
In study period 1, patients received either the early combination treatment with metformin (stable daily dose of 1000 mg, 1500 mg, or 2000 mg) and vildagliptin 50 mg twice daily, or standard-of-care initial metformin monotherapy (stable daily dose of 1000 mg, 1500 m …
In study period 1, patients received either the early combination treatment with metformin (stable daily dose of 1000 mg, 1500 mg, or …
Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial.
Mueller NT, Differding MK, Zhang M, Maruthur NM, Juraschek SP, Miller ER 3rd, Appel LJ, Yeh HC. Mueller NT, et al. Diabetes Care. 2021 Jul;44(7):1462-1471. doi: 10.2337/dc20-2257. Epub 2021 May 18. Diabetes Care. 2021. PMID: 34006565 Free PMC article. Clinical Trial.
Effects were similar in comparison of the metformin group with the behavioral weight loss group. Metformin versus control also increased butyrate, acetate, and valerate at 6 months (but not at 12 months). ...Future research is needed to elucidate whether the gut mic …
Effects were similar in comparison of the metformin group with the behavioral weight loss group. Metformin versus control also …
Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS).
Fruzzetti F, Perini D, Russo M, Bucci F, Gadducci A. Fruzzetti F, et al. Gynecol Endocrinol. 2017 Jan;33(1):39-42. doi: 10.1080/09513590.2016.1236078. Epub 2016 Nov 3. Gynecol Endocrinol. 2017. PMID: 27808588 Clinical Trial.
Insulin resistance (IR) plays a pivotal role in PCOS. Insulin-sensitizer agents such as metformin and inositols have been shown to improve the endocrine and metabolic aspects of PCOS. ...No significant changes in acne and hirsutism were observed. The two insulin-sensitizer …
Insulin resistance (IR) plays a pivotal role in PCOS. Insulin-sensitizer agents such as metformin and inositols have been shown to im …
Metformin versus insulin for the treatment of gestational diabetes.
Rowan JA, Hague WM, Gao W, Battin MR, Moore MP; MiG Trial Investigators. Rowan JA, et al. N Engl J Med. 2008 May 8;358(19):2003-15. doi: 10.1056/NEJMoa0707193. N Engl J Med. 2008. PMID: 18463376 Free article. Clinical Trial.
RESULTS: Of the 363 women assigned to metformin, 92.6% continued to receive metformin until delivery and 46.3% received supplemental insulin. ...There were no serious adverse events associated with the use of metformin. CONCLUSIONS: In women with gestational …
RESULTS: Of the 363 women assigned to metformin, 92.6% continued to receive metformin until delivery and 46.3% received supple …
Metformin Improves Peripheral Insulin Sensitivity in Youth With Type 1 Diabetes.
Cree-Green M, Bergman BC, Cengiz E, Fox LA, Hannon TS, Miller K, Nathan B, Pyle L, Kahn D, Tansey M, Tichy E, Tsalikian E, Libman I, Nadeau KJ. Cree-Green M, et al. J Clin Endocrinol Metab. 2019 Aug 1;104(8):3265-3278. doi: 10.1210/jc.2019-00129. J Clin Endocrinol Metab. 2019. PMID: 30938764 Free PMC article. Clinical Trial.
We previously demonstrated that adolescents with type 1 diabetes have adipose, hepatic, and muscle IR, and that metformin lowers daily insulin dose, suggesting improved IR. However, whether metformin improves IR in muscle, hepatic, or adipose tissues in type 1 diabe …
We previously demonstrated that adolescents with type 1 diabetes have adipose, hepatic, and muscle IR, and that metformin lowers dail …
Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status.
Cameron AR, Morrison VL, Levin D, Mohan M, Forteath C, Beall C, McNeilly AD, Balfour DJ, Savinko T, Wong AK, Viollet B, Sakamoto K, Fagerholm SC, Foretz M, Lang CC, Rena G. Cameron AR, et al. Circ Res. 2016 Aug 19;119(5):652-65. doi: 10.1161/CIRCRESAHA.116.308445. Epub 2016 Jul 14. Circ Res. 2016. PMID: 27418629 Free PMC article. Clinical Trial.
Metformin suppressed IKKalpha/beta activation, an effect that could be separated from some metabolic actions, in that BI605906 did not mimic effects of metformin on lipogenic gene expression, glucose production, and AMP-activated protein kinase activation. ...CLINIC
Metformin suppressed IKKalpha/beta activation, an effect that could be separated from some metabolic actions, in that BI605906 did no
The influence of telmisartan on metformin pharmacokinetics and pharmacodynamics.
Wen J, Zeng M, Liu Z, Zhou H, Xu H, Huang M, Zhang W. Wen J, et al. J Pharmacol Sci. 2019 Jan;139(1):37-41. doi: 10.1016/j.jphs.2018.11.007. Epub 2018 Nov 25. J Pharmacol Sci. 2019. PMID: 30538075 Free article. Clinical Trial.
Metformin is the most widely used drug among type 2 diabetes mellitus patients. ...Blood samples from various time-points after drug adminstration were analyzed for metformin quantification. Oral glucose tolerance test (OGTT) was conducted 2 h after metformin
Metformin is the most widely used drug among type 2 diabetes mellitus patients. ...Blood samples from various time-points after drug
Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD).
Perrone RD, Abebe KZ, Watnick TJ, Althouse AD, Hallows KR, Lalama CM, Miskulin DC, Seliger SL, Tao C, Harris PC, Bae KT. Perrone RD, et al. Kidney Int. 2021 Sep;100(3):684-696. doi: 10.1016/j.kint.2021.06.013. Epub 2021 Jun 27. Kidney Int. 2021. PMID: 34186056 Clinical Trial.
Twenty-one participants in the metformin arm reduced drug dose due to inability to tolerate, compared with 14 in the placebo arm (not significant). ...Thus, metformin in adults with ADPKD was found to be safe and tolerable while slightly reducing estimated GFR decli …
Twenty-one participants in the metformin arm reduced drug dose due to inability to tolerate, compared with 14 in the placebo arm (not …
3,576 results